Editorial
doi: 10.1016/j.jacc.2016.11.036.
Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?
Affiliations
- PMID: 28153103
- DOI: 10.1016/j.jacc.2016.11.036
Item in Clipboard
Editorial
Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?
J Am Coll Cardiol.
.
Free article
No abstract available
Keywords: LDL cholesterol; PCSK9 inhibitors; adverse effects; lipids.
Comment on
-
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.J Am Coll Cardiol. 2017 Feb 7;69(5):471-482. doi: 10.1016/j.jacc.2016.11.037. J Am Coll Cardiol. 2017. PMID: 28153102
Similar articles
-
Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.J Am Heart Assoc. 2015 Jun 15;4(6):e001937. doi: 10.1161/JAHA.115.001937. J Am Heart Assoc. 2015. PMID: 26077586 Free PMC article.
-
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).J Am Coll Cardiol. 2014 Feb 11;63(5):430-3. doi: 10.1016/j.jacc.2013.09.048. Epub 2013 Oct 23. J Am Coll Cardiol. 2014. PMID: 24161333 Clinical Trial.
-
Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.Intern Med J. 2017 Aug;47(8):856-865. doi: 10.1111/imj.13451. Intern Med J. 2017. PMID: 28401639 Review.
-
Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.Pharmacol Res. 2015 Dec;102:168-75. doi: 10.1016/j.phrs.2015.09.021. Epub 2015 Oct 8. Pharmacol Res. 2015. PMID: 26455563 Review.
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
Cited by
-
Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors.Eur Cardiol. 2017 Aug;12(1):30-32. doi: 10.15420/ecr.2017.12.1.GE3. Eur Cardiol. 2017. PMID: 30416548 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
